Business
Contact Levi & Korsinsky by September 15, 2025 Deadline to Join Class Action Against Capricor Therapeutics, Inc.(CAPR)
Contact Levi & Korsinsky by September 15, 2025 Deadline to Join Class Action Against Capricor...
About this update from Caprock Mining Corp
[{"type":"text","content":"Contact Levi & Korsinsky by September 15, 2025 Deadline to Join Class Action Against Capricor Therapeutics, Inc.(CAPR)\n\n\n\n Contact Levi & Korsinsky by September 15, 2025 Deadline to Join Class Action Against Capricor Therapeutics, Inc.(CAPR)\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n\n\n\n\n Contact Levi & Korsinsky by September 15, 2025 Deadline to Join Class Action Against Capricor Therapeutics, Inc.(CAPR)\n \n\n PR Newswire\n \n\n\n\n\n\n NEW YORK\n \n\n ,\n \n\n Aug. 12, 2025\n \n\n /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in\n \n Capricor Therapeutics, Inc.\n \n (\"Capricor\" or the \"Company\") (NASDAQ: CAPR) of a class action securities lawsuit.\n \n\n\n\n\n\n\n\n\n\n CLASS DEFINITION:\n \n The lawsuit seeks to recover losses on behalf of Capricor investors who were adversely affected by\n \n alleged\n \n securities\n \n fraud\n \n between\n \n October 9, 2024\n \n and\n \n July 10, 2025\n \n . Follow the link below to get more information and be contacted by a member of our team:\n \n\n\n https://zlk.com/pslra-1/capricor-therapeutics-inc-lawsuit-submission-form-2?prid=160790&wire=4\n \n\n\n\n CAPR\n \n investors may also contact\n \n Joseph E. Levi, Esq.\n \n via email\n \n at [email protected] or\n \n by telephone at (212) 363-7500.\n \n\n\n CASE DETAILS:\n \n According to the complaint, defendants provided investors with material information concerning Capricor's lead cell therapy candidate drug deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Defendants' statements included, among other things, Capricor's ability to obtain a Biologics License Application (BLA) for deramiocel from the U.S. Food and Drug Administration (FDA). Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel.   On\n \n July 11, 2025\n \n , Capricor issue...